Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade the company's valuation. Learn more on BHC stock here.

Bausch+Lomb ($BLCO), a contact lens supplier, is exploring a sale to address concerns raised by its lenders like Apollo Global Management ($APO)

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned to offload the remainder of shares by striking a deal with its investors to exchange Bausch Health stock for Bausch + Lomb stock.

The stock of eyecare company Bausch + Lomb Corp. was up 18% early Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its indebted parent.

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.

Bausch + Lomb is working with advisers from Goldman Sachs to test interest from possible buyers, the Financial Times reported on Saturday.

Key Takeaways Bausch + Lomb is discussing a possible sale that would separate it from its parent company, Bausch Health Cos.Bausch Health is saddled with debt of $21 billion, nearly $10 billion of which is set to mature in 2027.

Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with significant debt, as per a Financial